Dicerna appoints Martin Freed to board of directors
The board of directors determined Dr. Freed is an independent director. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015.
Dr. Freed was a co-founder and served as chief medical officer of Civitas Therapeutics, Inc., from December 2010 to October 2014 (acquired by Acorda Therapeutics, Inc., or Acorda) and as senior vice president, clinical development of Acorda from October 2014 through January 2015.
From December 2009 through December 2010, Dr. Freed served as acting chief medical officer of Avila Therapeutics, Inc. From May 2009 through February 2010, Dr. Freed served as a consultant and acting chief medical officer to Taligen Therapeutics, or Taligen, relating to clinical development, including strategic and operational planning and execution.
Prior to consulting for Taligen, Dr. Freed served as chief medical officer of Adnexus Therapeutics, Inc., (acquired by Bristol-Myers Squibb) from June 2007 to September 2008, where he provided executive and medical leadership for clinical pharmacology and development strategy.
He served and as chief medical officer of Vitae Pharmaceuticals, Inc., or Vitae, from April 2005 to January 2007, where he led aspects of preclinical and clinical development and defined the strategic direction of the company, representing clinical and regulatory functions and the building of external relations.
Before Vitae, he spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals or SmithKline Beecham, where he served numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area.
He served as an independent board director of InteKrin Therapeutics, Inc., from 2007 through 2010. Dr. Freed has authored over 100 publications or presentations.
Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital.
A Fellow of the American College of Physicians, he received his B.S. with Distinction in Biology from the University of Delaware and M.D. from Pennsylvania State University's College of Medicine. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST